PHARMACEUTICAL PREPARATIONS CELL TRANSPLANT

Brand Owner (click to sort) Address Description
AATGAFTA CSL BEHRING 1020 First Avenue King of Prussia PA 19406 Pharmaceutical preparations for cell transplant conditions; Pharmaceutical preparations for transplant conditions;
AATRUSCA CSL BEHRING 1020 First Avenue King of Prussia PA 19406 Pharmaceutical preparations for cell transplant conditions; Pharmaceutical preparations for transplant conditions;
COHIXEV CSL BEHRING 1020 First Avenue King of Prussia PA 19406 Pharmaceutical preparations for cell transplant conditions; Pharmaceutical preparations for transplant conditions;
ENHICTUS CSL BEHRING 1020 First Avenue King of Prussia PA 19406 Pharmaceutical preparations for cell transplant conditions; Pharmaceutical preparations for transplant conditions;
IMMGAFTA CSL BEHRING 1020 First Avenue King of Prussia PA 19406 Pharmaceutical preparations for cell transplant conditions; Pharmaceutical preparations for transplant conditions;
KIXODY CSL BEHRING 1020 First Avenue King of Prussia PA 19406 Pharmaceutical preparations for cell transplant conditions; Pharmaceutical preparations for transplant conditions;
MIRGAFTA CSL BEHRING 1020 First Avenue King of Prussia PA 19406 Pharmaceutical preparations for cell transplant conditions; Pharmaceutical preparations for transplant conditions;
SUSBRIGEO CSL BEHRING 1020 First Avenue King of Prussia PA 19406 Pharmaceutical preparations for cell transplant conditions; Pharmaceutical preparations for transplant conditions;
XAATIVITY CSL BEHRING 1020 First Avenue King of Prussia PA 19406 Pharmaceutical preparations for cell transplant conditions; Pharmaceutical preparations for transplant conditions;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. Cell preparations comprising a plurality of apoptotic EBV-transformed B lymphocytes and methods of producing cell preparations comprising a plurality of apoptotic EBV-transformed B lymphocytes. The methods comprise transforming B lymphocytes with EBV, incubating the transformed B lymphocytes with a flavin N-oxide photosensitizer, adding a non-toxic antioxidant, and exposing the lymphocytes to an activator, such as photoradiation of an appropriate wavelength to activate the photosensitizer. Also provided are methods of using the apoptotic EBV-transformed B lymphocyte cell preparations to elicit production of EBV-specific T cells in human patients. Finally, methods of treating organ transplant patients, specifically children, comprising administering an effective amount of the apoptotic EBV-transformed B-lymphocyte cell preparation to the patient prior to transplantation are provided.